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Background: Previous studies have shown that class-I histone deacetylase (HDAC) 8 mRNA is upregulated in
urothelial cancer tissues and urothelial cancer cell lines compared to benign controls. Using urothelial cancer cell
lines we evaluated whether specific targeting of HDAC8 might be a therapeutic option in bladder cancer
treatment.
Methods: We conducted siRNA-mediated knockdown and specific pharmacological inhibition of HDAC8 with the
three different inhibitors compound 2, compound 5, and compound 6 in several urothelial carcinoma cell lines with
distinct HDAC8 expression profiles. Levels of HDAC and marker proteins were determined by western blot analysis
and mRNA levels were measured by quantitative real-time PCR. Cellular effects of HDAC8 suppression were
analyzed by ATP assay, flow cytometry, colony forming assay and migration assay.
Results: Efficient siRNA-mediated knockdown of HDAC8 reduced proliferation up to 45%. The HDAC8 specific inhibitors
compound 5 and compound 6 significantly reduced viability of all urothelial cancer cell lines (IC50 9 – 21 μM). Flow
cytometry revealed only a slight increase in the sub-G1 fraction indicating a limited induction of apoptosis. Expression
of thymidylate synthase was partly reduced; PARP-cleavage was not detected. The influence of the pharmacological
inhibition on clonogenic growth and migration show a cell line- and inhibitor-dependent reduction with the strongest
effects after treatment with compound 5 and compound 6.
Conclusions: Deregulation of HDAC8 is frequent in urothelial cancer, but neither specific pharmacological inhibition
nor siRNA-mediated knockdown of HDAC8 impaired viability of urothelial cancer cell lines in a therapeutic useful
manner. Accordingly, HDAC8 on its own is not a promising drug target in bladder cancer.
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Bladder cancer is the seventh most common cancer type
worldwide with about 300,000 newly diagnosed cases
per year [1]. One-third of the patients are diagnosed
with a muscle invasive carcinoma and up to 50% of pa-
tients already present with or developed metastases
within the first two years. While patients with a non-
muscle invasive papillary urothelial carcinoma expect a
rather good prognosis, long term survival of patients
suffering from metastatic disease does not exceed 20%
[2]. Although significant responses rates are observed* Correspondence: Guenter.Niegisch@med.uni-duesseldorf.de
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available in this article, unless otherwise statedafter treatment with cisplatin based combination chemo-
therapy, the majority of patients will develop disease re-
currence presenting with cisplatin resistance [3-5].
Epigenetic alterations have been proposed as a driving
force of malignancy [6-8]. In particular, histone deacetylases
(HDACs) are associated with the development and progres-
sion of several cancer types [9,10]. The human HDAC fam-
ily is composed of 18 genes and is classified based on the
sequence homology to their yeast orthologues Rpd3, HdaI
and Sir2 and their domain organization: HDAC1, HDAC2,
HDAC3 and HDAC8 (class I); HDAC4, HDAC5, HDAC7
and HDAC9 (class IIa); HDAC6 and HDAC10 (class II b);
HDAC11 (class IV) and seven sirtuins (class III) [11-13].
The classical HDACs catalyze the Zn2+ dependent deacety-
lation of acetyl-lysine residues [11]. Expression profiles ofral Ltd; licensee BioMed Central Ltd. This is an Open Access article distributed
tribution License (http://creativecommons.org/licenses/by/4.0), which permits
n in any medium, provided the original work is properly credited. The Creative
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
.
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e.g. gastric, prostate and ovarian cancer [14-16]. In gen-
eral, HDACs are considered to act as transcriptional co-
repressors because high HDAC activity is associated with
transcriptionally inactive chromatin [17,18]. Although many
HDACs deacetylate histones the analysis of the human
acetylome indicates that the deacetylation of non-histone
proteins represents a considerable part of their action
[19,20]. Substrates include p53 [21], cohesion subunit
SMC3 [22] and α-tubulin [23]. HDAC inhibitors are
useful in the therapy of several hematological malignan-
cies and are currently also investigated in the treatment of
solid cancers [24,25].
The expression of HDAC8 has been described in a variety
of cancer entities e.g. colon, breast lung, pancreas and ovary
cancer [26]. HDAC8 is the most recently identified class I
HDAC. It is a protein of 377 amino acids and contains a
NLS in the center of the catalytic domain [27-29]. HDAC8
has a conserved motif for phosphorylation by protein kin-
ase A (PKA), which negatively impacts its catalytic activity
[30,31]. While class I HDAC family members form nuclear
multiprotein complexes that interact with other chromatin
modifiers and transcription factors, HDAC8 has not been
found to do so [17]. Its intracellular localization seems
to depend on the cell type. In gastric adenocarcinoma,
esophageal squamous carcinoma, prostate adenocarcin-
oma and breast carcinoma HDAC8 localization has been
described as both nuclear and cytosolic but as exclusively
nuclear for non-cancerous gastric, esophageal or prostate
epithelium [26]. A predominantly cytosolic distribution of
HDAC8 was described for prostate cancer cells [32] and
for differentiating smooth muscle cells [33].
In the highly malignant childhood cancer neuroblastoma
high HDAC8 expression significantly correlates with poor
prognostic markers and poor overall and event-free
survival. In cultured neuroblastoma cells knockdown
and pharmacological inhibition of HDAC8 resulted in
inhibition of proliferation, reduced clonogenic growth,
cell cycle arrest and differentiation [34]. Furthermore,
HDAC8 specific inhibition selectively induces apoptosis in
T-cell derived lymphoma and leukemic cells [35]. In hepa-
tocellular carcinoma overexpression of HDAC8 promotes
proliferation and inhibits apoptosis. HDAC8 knockdown
inhibits proliferation and enhances apoptosis in hepatocel-
lular carcinoma cells via up-regulation of p53 [36]. In
human breast cancer cell lines overexpression of HDAC1,
HDAC6 or HDAC8 contributes to increased invasion and
metalloproteinase-9 (MMP-9) expression [37]. Furthermore,
HDAC8 promotes lung, colon and cervical cancer cell pro-
liferation [31] and may regulate telomerase activity [38].
A recently published analysis of HDAC expression
patterns in urothelial carcinoma cell lines and tissues
showed a deregulation of several HDACs in urothelial
cancer. These findings include up-regulation of HDAC2and HDAC8 and down-regulation of HDAC4, HDAC5,
and HDAC7 [39]. Given the promising results in neuro-
blastoma [35], we sought to determine whether the select-
ive targeting of HDAC8 might serve as an appropriate
therapy for urothelial carcinoma.
Methods
Cell culture and treatment
The urothelial cancer cell lines (UCCs) VM-CUB1, RT-112,
SW-1710, 639-V and UM-UC-3 were cultured in
DMEM GlutaMAX-I (Gibco, Life Technologies, Darmstadt,
Germany) supplemented with 10% fetal calf serum
(GE Healthcare, Piscataway, NJ) at 37°C and 5% CO2. Cell
lines used were provided by Dr. M. A. Knowles (Leeds,
UK), Dr. J. Fogh (New York, USA), Dr. Barton Grossmann
(Houston, USA) and by the DSMZ (Braunschweig,
Germany). Normal urothelial control (NUC) cells were
isolated from ureters after nephrectomy and were cul-
tured in keratinocyte serum-free medium (Invitrogen,
Life Technologies, Darmstadt, Germany) supplemented
with 0.25 ng/ml epidermal growth factor and 12.5 μg/ml
bovine pituitary extract [40].
Experiments with inhibitors were performed 24 h after
seeding of the cells with a single dose of the selective
HDAC8-inhibitors compound 2 (c2; 1-napthohydroxamic
acid, (abcr GmbH & Co, Karlsruhe, Germany), compound
5 (c5, δ-naphtyl-trans 2-butenoil hydroxamic acid) and
compound 6 (c6, 4-naphtyl-benzoil hydroxamic acid) or the
pan HDAC-inhibitor SAHA (suberoylanilide hydroxamic
acid; #1009929, Cayman Chemicals, Ann Arbor, MI). C5
and c6 are investigational compounds (described in [41])
and are available on request. Inhibitors were dissolved
in DMSO as a stock of 10 mM. Control cells were
treated with DMSO only.
SiRNA mediated knockdown of HDAC8
UCCs were seeded in 6-well plates and grown for 24 h
before transfection. Cells were transfected with 10 nM
HDAC8 Silencer® Select validated siRNA (#4390824,
s31698, Ambion, Life Technologies, Darmstadt, Germany)
or a Silencer® Select Negative Control #2 validated
siRNA (#4390846, Ambion, Life Technologies, Darmstadt,
Germany) using Lipofectamine RNAi MAX (Invitrogen,
Life Technologies, Darmstadt, Germany), according to
the manufacturer’s protocol. After transfection cells were
incubated for 72 h before use for further experiments.
Determination of mean inhibitory concentrations (IC50)
and viability
The mean inhibitory concentrations (IC50) and cell viability
were measured trough total cellular ATP as an indicator
for viable cells using the CellTiter-Glo® Luminescent Cell
Viability Assay (Promega, Mannheim, Germany). UCCs
were seeded into 96-well plates and grown for 24 h before
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or DMSO and further grown for 72 h. In another experi-
ment, cells were plated in 6-well plates and grown for 24 h
before siRNA-mediated knockdown of HDAC8. Viability
measurements were performed after 72 h by transferring
the cells into 96-well plates using CellTiter-Glo Reagent ac-
cording to manufacturer’s protocol in a Wallac Victor 1420
Multilabel Counter (PerkinElmer, Rodgau, Germany).
Colony forming assay and Giemsa-staining
The colony forming assay was carried out 72 h after siRNA
mediated HDAC8 knockdown and HDAC8 inhibitor treat-
ment. Then, cells were plated in 6-well plates at a density of
500 to 1,000 cells per well. After 10 days, cells were washed
with PBS (Biochrom, Merck Millipore, Berlin, Germany),
shortly fixed in 50% methanol and incubated for 10
min in 100% methanol. The colonies were stained with
Giemsa (Merck, Darmstadt, Germany). Colony num-
ber and size was determined with ImageJ software
(http://rsbweb.nih.gov/ij/).
Cell cycle analysis by flow cytometry
UCCs were transfected with HDAC8 siRNA or an irrele-
vant control siRNA or, in another experiment, cultured
with the determined IC50 concentrations of the HDAC8
selective inhibitors c2, c5 and c6, the pan HDAC-inhibitor
SAHA (2.5 μM) or DMSO. Cell cycle analysis was per-
formed after 72 h by staining the attached cells and
cells in the supernatant with a PI-buffer containing 50
μg/ml propidium iodide, 0.1% sodium citrate and 0.1%
Triton X-100 [42] and flow cytometry using a BD LSR
Fortessa cell analyzer system and FACSDiva software
6.2 (Becton Dickinson Biosciences, Heidelberg, Germany).
Migration assay
Cell migration was determined in wound healing assays by
means of Ibidi Culture-Insert (Ibidi, Martinsried, Germany).
The cell suspension was placed in both compartments
allowing growth in the designated area only. The cells were
treated with IC50 concentrations of c2, c5, c6 or 2.5 μM
SAHA 48 h prior to plating. The Culture-Insert was re-
moved 24 h after cell attachment creating a cell-free gap
of approximately 500 μm in a confluent cell layer. The
extent of wound closure was examined by phase con-
trast microscopy with the LuciaG software (Laboratory
Imaging s.r.o., Prague, Czech Republic) at time points 0,
3, 6, 9, 12 and 24 h.
RNA isolation and quantitative real-time PCR
Total RNA from cell culture was isolated by the Qiagen
RNeasy Mini Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s protocol. Synthesis of cDNA was
performed using QuantiTect Reverse Transcription Kit
(Qiagen, Hilden, Germany) with an extended incubationtime of 30 min at 42°C. QRT-PCR was performed using
an ABI 7500 Fast PCR instrument (Life Technologies,
Darmstadt, Germany) with QuantiTect SYBR Green
RT-PCR Kit (Qiagen, Hilden, Germany) according to the
manufacture’s protocol. To determine the expression levels
of HDAC1 (#QT00015239), HDAC2 (#QT00001890),
HDAC3 (#QT00093730) and HDAC8 (#QT00049630) we
used QuantiTect Primer assays (Qiagen, Hilden, Germany)
at an annealing temperature of 55°C. The expression of the
housekeeping gene TATA-box binding protein (TBP)
was determined with self-designed primers (forward:
5’-ACAACAGCCTGCCACCTTA-3’; reverse: 5’-GAATA
GGCTGTGGGTCAGT-3’). Technical duplicates had less
than 10% standard deviation.
Western blot analysis
Western blot analysis of whole-cell extracts were done
as described previously [39]. Total protein was extracted by
cell lysis in a RIPA-buffer containing 150 mM NaCl, 1%
Triton X-100, 0.5% desoxycholate, 1% Nonidet P-40, 0.1%
SDS, 1 mM EDTA, 50 mM Tris (pH 7,6) and a protease in-
hibitor cocktail (10 μl/ml, #P-8340, Sigma-Aldrich) for 30
minutes on ice. Protein concentrations were determined
by BCA protein assay (Thermo Scientific, Rockford, IL).
After separation in SDS-page gels and transfer to PVDF
membranes (Merck Millipore, Berlin, Germany) the
membranes were blocked with 5% non-fat milk in TBST
(150 mM NaCl, 10 mM Tris, pH 7.4 and 0.1% Tween-20),
washed and then incubated with primary antibodies at
room temperature for 1 h or at 4°C over night. Primary
antibodies were used against HDAC1 (1:1,000, C-19,
sc-6298; Santa Cruz Biotechnology, Heidelberg, Germany),
HDAC2 (1:5,000, H-54, sc-7899; Santa Cruz Biotechnology,
Heidelberg, Germany), HDAC3 (1:1,000, H-99, sc-11417;
Santa Cruz Biotechnology, Heidelberg, Germany), HDAC8
(1:400, A-4008; Epigentek, Brooklyn, NY), p21 (1:400, C-19,
sc-397; Santa Cruz Biotechnology, Heidelberg, Germany),
thymidylate synthase (1:1,000, TS, TS106, Millipore,
Temecula, CA), PARP (poly [ADP-ribose] polymerase
1, 1:500, 46D11; Cell Signaling Technology, Inc., Danvers,
MA) and acetylated α-tubulin (1:15,000, #T-7451, Sigma
Aldrich, St. Louis, Mo). Anti-α-Tubulin B-512 (Sigma
Aldrich, St. Louis, MO) was used as loading control in
a concentration of 1:50,000. Secondary antibodies were
HRP-conjugated goat-anti-mouse antibody (sc-2005;
Santa Cruz Biotechnology, Heidelberg, Germany), HRP-
conjugated goat-anti-rabbit antibody (sc-2004, Santa Cruz
Biotechnology, Heidelberg, Germany) and HRP-conjugated
rabbit-anti-goat antibody (P0160; DakoCytomation,
Stockholm, Sweden) at a concentration of 1:10,000 to
1:100,000. Bands were visualized by the ECL select
chemo luminescence kit (GE Healthcare, Piscataway, NJ)
and the WesternBright Quantum kit (Biozym, Hessisch
Oldendorf, Germany).
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Histones were extracted following a published protocol
through sulphuric acid extraction and TCA-precipitation
[43]. One μg of each sample was used for western blot
analysis with 15% SDS-PAGE gels and PVDF membranes
(Merck Millipore, Berlin, Germany) according to the
previously-described protocol. The detection of acetylated
and non-acetylated histones was performed with primary
antibodies against acetylated histone H3 (1:2,000, #39139,
Active Motif, La Hulpe, Belgium), total histone H3
(1:1,000, #3638, Cell Signaling Technology, Inc., Danvers,
MA), acetylated histone H4 (1:1,000, #39243, Active Motif,
La Hulpe, Belgium) and total histone H4 (1:500, #39269,
Active Motif, La Hulpe, Belgium).Figure 1 HDAC8 expression in urothelial cancer cell lines.
(A) Relative mRNA expression of HDAC8 in eight urothelial cancer
cell lines (UCCs) compared to two normal uroepithelial cultures
(NUC; mean value set as 1) measured by quantitative RT-PCR. The
HDAC8 expression values were adjusted to TBP as a referenceStatistical analysis
Statistical analyses were performed using SPSS 18
(SPSS, Chicago, USA). Significance was measured by
the student’s t-test and no-parametric Mann-Whitney
U test. P-values of < 0.05 were considered as significant
whereas p < 0.01 and p < 0.001 were defined as highly
significant. IC50 values and dose-response curves were
approximated by non-linear regression analysis using
Origin 8.0 (Origin Lab, Northhampton, GB).gene and are displayed on the y-axis. The dotted line shows the
average expression level of the NUC samples. (B) Protein expression of
HDAC8 in urothelial cancer cell lines (UCCs) and a normal uroepithelial
control (NUC) analyzed by western blotting. As a loading control
α-tubulin was stained on each blot.Results
HDAC8 mRNA and protein expression in urothelial cancer
cell lines and uroepithelial cells
Urothelial bladder cancer is a heterogeneous disease
with diverse clinical, pathological, genetic and epigenetic
presentations. As recently published [39], overexpression
of HDAC8 was observed in cancer tissues. In urothelial
cancer cell lines, a variable expression of HDAC8 was
observed both at mRNA and protein level.
To cover this range, we chose a panel of cell lines
representing the heterogeneity of the tumor. The mRNA
level of HDAC8 was more than twofold upregulated in
the UCC UM-UC-3 compared to NUCs. In contrast, UCC
RT-112 cells showed a decreased level of HDAC8 mRNA
(Figure 1A). The HDAC8 mRNA expression in UCCs was
comparable to the measured HDAC8 expression in other
tumor entities such as neuroblastoma and mammary
carcinoma (data not shown). The HDAC8 protein levels
are shown in Figure 1B. The UCC SW-1710 indicated a
strong increase of HDAC8 protein compared to NUCs.
The cell lines VM-CUB1 and UM-UC-3 showed a moder-
ate increase of HDAC8. In the cell line 639-V, a reduction
of HDAC8 protein expression was observed.
Accordingly the urothelial carcinoma cell lines SW-1710
(protein level strongly increased), UM-UC-3, VM-CUB1
(protein level moderately increased), RT-112 (protein level
as normal) and 639-V (protein level decreased) were
selected for further experiments.Effects of siRNA-mediated knockdown of HDAC8 on cell
proliferation and clonogenic growth of urothelial
carcinoma cells
The endogenous HDAC8 expression was reduced by tran-
siently transfecting HDAC8 siRNA and irrelevant siRNA
into RT-112, VM-CUB1, SW-1710, 639-V and UM-UC-3
cells. The knockdown efficacy 72 h after transfection was
shown by RT-PCR (Figure 2A) and western blot analysis
(Figure 2B). The UCCs RT-112, VM-CUB1, SW-1710 and
UM-UC-3 indicated a HDAC8 knockdown of about 90%
to 95%. In 639-V cells, a knockdown of 55% was achieved.
To investigate the impact of HDAC8 on cell proliferation
of UCCs we performed viability assays after 72 h of
transfection. Targeting HDAC8 with siRNA caused a
20% to 45% reduction of cell growth compared to the
irrelevant control (Figure 3A). Colony forming assays were
performed to evaluate the role of HDAC8 for anchorage-
dependent clonal growth capability. The siRNA mediated
HDAC8 knockdown inhibited clonogenic growth of UCCs
(Figure 3B). The transfection of HDAC8 siRNA in VM-
CUB1 and UM-UC-3 cells caused a moderate reduction
of colony numbers compared to transfection of irrelevant
siRNA by up to 30%. The relative size of the HDAC8
Figure 2 Efficiency of HDAC8 knockdown by a specific siRNA in the urothelial cancer cell lines. (A) Relative HDAC8 expression after siRNA
mediated knockdown in urothelial carcinoma cell lines compared to irrelevant control as examined by quantitative RT-PCR analysis (72 h). The
HDAC8 expression values were normalized to TBP as a reference gene and are displayed on the y-axis. p < 0.01 and p < 0.001 were defined as
highly significant and marked as * and **. (B) Western blot analysis confirmed the effects of HDAC8-siRNA mediated knockdown at the HDAC8
protein level in comparison to normal and irrelevant siRNA controls (72 h). As a loading control α-tubulin was stained on each blot.
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parison to irrelevant siRNA. In VM-CUB1, SW-1710,
RT-112 and UM-UC-3 cells the colony size remains
constant between irrelevant control and HDAC8 siRNA
transfection (data not shown).Figure 3 Proliferation and clonogenicity in urothelial cancer cells afte
several urothelial carcinoma cell lines after siRNA mediated knockdown of
cells was measured by ATP-assay and is displayed on the y-axis. p < 0.01 an
(B) Giemsa-staining of colonies from irrelevant siRNA and HDAC8 siRNA tra
compared to an untreated control (72 h).To characterize the effect of the HDAC8 knockdown
on UCCs, we investigated downstream targets of HDAC8
known from other cancers: the proliferation marker thy-
midylate synthase (TS), cleavage of PARP and expression
of p21. In addition, we examined the acetylation status ofr siRNA mediated knockdown of HDAC8. (A) Relative cell viability in
HDAC8 compared to irrelevant control (72 h). The percentage of viable
d p < 0.001 were defined as highly significant and marked as * and **.
nsfected RT-112, VM-CUB1, SW-1710, 639-V and UM-UC-3 cells
Table 1 Stated are IC50 values after 72 h of HDAC8
inhibitor treatment in eight urothelial cancer cell lines
and a representative normal uroepithelial control
IC50 [μM] Compound 2 Compound 5 Compound 6
VM-CUB1 ≥ 50 18.7 16
SW-1710 ≥ 50 20.8 18.8
RT-112 ≥ 50 9.7 9.1
639-V ≥ 50 12.6 18.6




≥ 50 24.2 10.2
Lehmann et al. Journal of Experimental & Clinical Cancer Research 2014, 33:59 Page 6 of 14
http://www.jeccr.com/content/33/1/59α-tubulin to estimate the specificity of the HDAC8 treat-
ment (Figure 4). The expression of TS 72 h after HDAC8
knockdown was only slightly reduced in SW-1710, 639-V
and UM-UC-3 cells. In RT-112 and VM-CUB1 cells no ef-
fects were observed. Effects on cleavage of PARP could only
be detected in UM-UC-3 cells after HDAC8 knockdown.
There a decrease can be observed. The expression level of
p21 indicates a decreased expression in comparison to ir-
relevant control in the cell lines RT-112, VM-CUB1, 639-V
and UM-UC-3 after HDAC8 knockdown. In the cell line
SW-1710 no altered p21 expression could be observed. An
increase of acetylated α-tubulin could be detected in all cell
lines after HDAC8 siRNA transfection (Figure 4).
Effects of HDAC8 specific hydroxamic acid inhibitors on
urothelial carcinoma cells
Based on the observation that the HDAC8 knockdown
inhibited proliferation of urothelial carcinoma cells we
investigated the sensitivity of several UCCs to three dif-
ferent HDAC8 inhibitors [41]. The treatment with the
HDAC8 selective small molecule inhibitors c2, c5 and c6
inhibited the cell proliferation of all UCCs in a concentra-
tion dependent manner, with stronger effects of the higher
affinity compounds c5 and c6 (Table 1). The three dose re-
sponse curves for the cell line RT-112 in Figure 5A show
a low sensitivity for c2 with a calculated IC50 value greater
than 50 μM and a higher sensitivity for c5 and c6 with an
IC50 value of about 9.7 μM and 9.1 μM.
While c5 and c6 significantly reduced the viability of
all UCCs, their effect varied among the cell lines. It is
noticeable that cells with an epithelial phenotype e.g. RT-
112 were more sensitive than cells with a mesenchymal
phenotype (SW-1710 and UM-UC-3; Figure 5B).
The influence of the inhibitors on clonogenic growth
after a 72 h treatment at the determined IC50 concentra-
tions is illustrated in Figure 6. Compound 2 inhibitedFigure 4 Effects of siRNA mediated HDAC8 knockdown on target pro
protein expression levels subsequent to HDAC8 knockdown were determin
the UCCs RT-112, VM-CUB1, SW-1710, 639-V and UM-UC-3 (72 h). As a loadclonogenicity only in VM-CUB1 cells. Treatment with
compound 5 resulted in a moderate reduction of colony
numbers in RT-112, UM-UC-3 and 639-V cells, whereas
in VM-CUB1 cells, clonogenic growth was completely
abolished. In contrast, c5 had no effect on SW-1710 cells.
Compound 6 was active in all cell lines, being most efficient
in VM-CUB1, UM-UC-3 and 639-V cells.
As the effect of pharmacological HDAC8 inhibition
was stronger than the effect of HDAC8 knock-down,
wound healing assays of UCCs after HDAC8 inhibitor
treatment were additionally performed (Figure 7A). A
clear difference was observed in VM-CUB1 and UM-UC-3
cells, respectively, comparing DMSO controls to cells
treated with c5 and c6, especially after 6 - 12 h (Figure 7B).
The impact of the HDAC8 inhibitor treatment was
further analyzed by western blot analysis of different
target proteins (Figure 8). The expression of thymidylate
synthase (TS) in VM-CUB1, SW-1710 and UM-UC-3 cells
was weakly reduced after 72 h of c5 and c6 treatment. No
effects were observed in 639-V and RT-112 cells. Increased
cleavage of PARP after c6 treatment could be only detected
in the UCC SW-1710. Effects on p21 were divergent. Inteins. PARP, p21, acetylated α-tubulin and thymidylate synthase (TS)
ed by western blot analysis in comparison to a irrelevant control in
ing control α-tubulin was stained on each blot.
Figure 5 Dose-dependent effects of three different HDAC8 specific inhibitors on viability of urothelial cancer cell lines. (A) Several
urothelial cancer cell lines were treated with different concentrations of HDAC8 inhibitors. Here, the dose-response curves of the UCC RT-112 are
shown for compound 2, compound 5 and compound 6 after 72 h inhibitor treatment as measured by ATP-assay (■ compound 2; ● compound
5; ▲ compound 6). The calculated IC50 value in this cell line for compound 2 is greater than 50 μM, for compound 5 it is 9.7 μM and for
compound 6 it is 9.1 μM. (B) Sensitivity of urothelial cancer cell lines and one representative normal uroepithelial control to compound 5 and
compound 6 after 72 h of treatment. The IC50 of compound 2 was only reached at concentrations near 50 μM. The cell lines outlined by bold
letters were used for the functional experiments.
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level could be observed. Expression decreased in the cell
lines SW-1710, 639-V and UM-UC-3 after c6 treatment
and in the two former cell lines also after c5 treatment
(Figure 8). An increase of acetylated α-tubulin was de-
tected in all cell lines after c5 and c6 inhibitor treat-
ment (Figure 8).Figure 6 Effect of HDAC8 specific inhibitor treatment on clonogenic g
from inhibitor treated RT-112, VM-CUB1, SW-1710, 639-V and UM-UC-3 cells
compound 6; IC50, 72 h).Effects of HDAC8 targeting on cell cycle and apoptosis in
urothelial cancer cell lines
To further characterize the impact of HDAC8 on cell
cycle distribution UCCs were analyzed by flow cytometry
after either knockdown or inhibitor treatment (Figure 9).
Knockdown of HDAC8 resulted in a significant shift in
cell cycle distribution only in SW-1710 cells, showingrowth of urothelial cancer cells. Giemsa-staining of grown colonies
is compared to DMSO solvent control (compound 2, compound 5,
Figure 7 Migration assay of urothelial cancer cells after HDAC8 inhibitor treatment. (A) Representative photographs of wound healing
assay at 0 and 12 hours from inhibitor treated RT-112, VM-CUB1, SW-1710, 639-V and UM-UC-3 cells (compound 2, compound 5, compound 6;
IC50, 72 h) in comparison to a DMSO solvent control (co). (B) Relative scratch size after 3, 6, 9 and 12 h of migration in comparison to the starting
point 0 h. The relative scratch size is displayed on the y-axis. p < 0.05 was regarded as significant and marked as *, whereas p < 0.01 and p < 0.001
were defined as highly significant and marked as ** and ***. The calculated significances refer to the DMSO solvent control.
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cant changes were observed (Figure 9A). In contrast,
pharmacological inhibition of HDAC8 by c5 and c6
resulted in a significant increase of the sub-G1 frac-
tion in the UCCs VM-CUB1 and SW-1710 and a sig-
nificant decrease of the G1-fraction in VM-CUB1,
SW-1710, 639-V and UM-UC-3 cells (Figure 9B). Fur-
ther, indications of a G2/M-arrest were observed after
c5 and c6 treatment in VM-CUB1, SW-1710, 639-V
and UM-UC-3 cells.Figure 8 Effects of specific HDAC8 inhibition on target proteins. PARP
(compound 2, compound 5, compound 6; IC50, 72 h) treated RT-112, VM-C
control were determined by western blot analysis. As a loading control α-tHDAC activity and compensation mechanism during
HDAC8 treatment
Following HDAC8 knockdown or pharmacological inhib-
ition, no effects on the acetylation status of histone H3
were observed (Figure 10). In contrast, acetylation of H4
increased after inhibitor treatment in RT-112 (Figure 10B).
In addition, a slight increase of H4 acetylation was observed
after c5 and c6 treatment in the cell line 639-V (Figure 10B).
No effects on the acetylation status of H4 were seen follow-
ing HDAC8 knockdown (Figure 10A)., p21, acetylated α-tubulin and thymidylate synthase (TS) in inhibitor
UB1, SW-1710, 639-V and UM-UC-3 cells compared to a DMSO solvent
ubulin was stained on each blot.
Figure 9 Effects of HDAC8 knockdown and HDAC8 inhibitor treatment on cell cycle distribution. Changes in cell cycle distribution and
amount of apoptotic cells (as sub-G1 fraction) after (A) siRNA mediated HDAC8 knockdown (72 h) and (B) HDAC8 inhibitor treatment
(compound 2, compound 5, compound 6; IC50, 72 h) were measured by cell cycle analysis using flow cytometry. DMSO served as a solvent
control. The relative distribution of the fractions is displayed on the y-axis.
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http://www.jeccr.com/content/33/1/59To investigate whether inhibition of HDAC8 might be
counteracted by concomitant upregulation of other class
I-HDACs (HDAC1, HDAC2 and HDAC3) their expres-
sion levels were compared by real-time PCR and western
blot analysis (Figures 11 and 12). In brief, HDAC1,
HDAC2 and HDAC3 mRNA levels exhibited variableFigure 10 Western blot analysis of histone H3 and H4 acetylation in u
inhibitor treatment. Amounts of acetylated and total histone H3 and H4
in the urothelial cancer cell lines RT-112, VM-CUB1, SW-1710, 639-V and UM-U
to untreated and irrelevant control and (B) pharmacological HDAC8 treatmen
a solvent control.changes after siRNA-mediated knockdown of HDAC8.
Both significant up-and downregulation of specific HDACs
were observed. In particular, either HDAC1 or HDAC2
seems to become upregulated after HDAC8 knockdown
(Figure 11A). Western blot analysis shown in Figure 11B
revealed a decrease of HDAC2 protein in RT-112 cellsrothelial cancer cell lines after HDAC8 knockdown and HDAC8
were analyzed by western blotting. The modifications are determined
C-3 after (A) siRNA mediated HDAC 8 knockdown (72 h) in comparison
t (compound 2, compound 5, compound 6; IC50, 72 h). DMSO served as
Figure 11 Compensation mechanism after HDAC8 knockdown in RT-112, VM-CUB1, SW-1710, 639-V and UM-UC-3 cells. Effects of siRNA
mediated HDAC8 knockdown on (A) mRNA and (B) protein expression levels of the class I histone deacetylase HDAC8, HDAC1, HDAC2 and
HDAC3 (72 h) in comparison to untreated and irrelevant control. The mRNA expression values were measured by quantitative RT-PCR analysis
and were normalized to TBP as a reference gene. p < 0.05 was regarded as significant and marked as *, whereas p < 0.01 and p < 0.001 were
defined as highly significant and marked as ** and ***. Protein expression levels were analyzed by western blotting, and α-tubulin was stained on
each blot as a loading control.
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http://www.jeccr.com/content/33/1/59and HDAC3 protein in UM-UC-3 cells after siRNA me-
diated HDAC8 knockdown. No significant deregulation
of other class I-HDACs took place (Figure 11B).
Measurements of mRNA expression after pharmaco-
logical inhibition of HDAC8 showed significant, but overall
slight decreases or increases of the expression of several
HDACs in the UCC (Figure 12A). Apart from a slightly
reduced expression of HDAC1 and HDAC2/3 in SW-1710
and VM-CUB1 cells, no changes of protein expression were
observed after c5 and c6 treatment (Figure 12B).Discussion
In this study we present the first systematic analysis of
HDAC8 expression and function in urothelial cancer using
a set of bladder cancer cell lines representative for the
heterogeneity of this tumor. The aim of our study was to
evaluate the potential of HDAC8 as a therapeutic target.
Overexpression of HDAC8 has been reported in a con-
siderable number of different cancer entities [26,34,36,37].
In neuroblastoma, in particular, HDAC8 expression was
significantly correlated with further poor prognostic
Figure 12 Compensation mechanism after specific HDAC8 inhibition in RT-112, VM-CUB1, SW-1710, 639-V and UM-UC-3 cells. Effects of
HDAC8 inhibitor treatment on (A) mRNA and (B) protein expression of the class I histone deacetylases HDAC8, HDAC1, HDAC2 and HDAC3,
compared to DMSO solvent control (compound 2, compound 5, compound 6; IC50, 72 h). The mRNA expression values were measured by
quantitative RT-PCR analysis and were normalized to TBP as a reference gene. p < 0.05 was regarded as significant and marked as *, whereas
p < 0.01 and p < 0.001 were defined as highly significant and marked as ** and ***. The calculated significances of the treated value refer to the
DMSO solvent control. Protein expression levels were analyzed by western blotting, and α-tubulin was stained on each blot as a loading control.
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http://www.jeccr.com/content/33/1/59markers as well as poor overall and progression-free
survival. SiRNA-mediated knockdown and pharmacological
inhibition of HDAC8 in neuroblastoma significantly
decreased proliferation rate and reduced clonogenic
growth, cell cycle arrest, and differentiation [34]. In hepa-
tocellular carcinoma HDAC8 knockdown also suppresses
cell proliferation and enhances apoptosis via elevated
expression of p53 and acetylation of p53 at Lys382 [36].
As there were indications from our own and other data
that HDAC8 is often upregulated in urothelial carcinoma
as well [39,44], the question arose whether HDAC8
might be a potential target for anticancer treatment in
this tumor.In urothelial cancer cell lines, a variable expression
of HDAC8 was observed both at mRNA and protein
level [39]. Importantly, mRNA expression levels were
comparable to neuroblastoma and breast cancer cells
(data not shown). An according variability has also been
reported from investigations in further malignomas, e.g.
hepatocellular carcinoma cell lines, were also a broad range
of HDAC8 expression was observed in cancer cell lines
[36]. Differences between mRNA and protein expression
indicate that HDAC8 expression and activity in UCCs may
be regulated both transcriptionally and on the protein level,
e.g. by protein kinase A (PKA) phosphorylation [30,31]. In
addition, in our UCC panel, a low HDAC8 expression was
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type. Therefore, to cover this range both on protein and
mRNA level, we chose to apply a panel of 6 cell lines repre-
senting the heterogeneity of the HDAC8 expression instead
of focusing on one urothelial cancer cell line.
SiRNA targeting of HDAC8 in UCCs caused a significant
reduction of proliferation up to 45% and inhibited clono-
genic growth in a cell line-dependent manner. These results
were comparable to observations in hepatocellular carcin-
oma (HCC) and neuroblastoma cells [34,36]. Clonogenic
growth was most decreased in the mesenchymal cell line
SW-1710 which presented the highest HDAC8 protein
expression. Treatment with the three different HDAC8
inhibitors c2, c5 and c6 revealed a low sensitivity of UCCs
for c2 with a calculated IC50 value greater than 50 μM. In
contrast, neuroblastoma cell lines (BE (2)-C) were more
sensitive to treatment with c2, presenting IC50 values in a
range of 10 to 40 μM. In these cells, the HDAC8 inhibitor
c2 yielded an similar phenotype at a concentration similar
to the in vitro IC50 of c2 against HDAC8 [41]. None of the
UCCs was inhibited substantially at this concentration by
pharmacological treatment with c2.
The inhibitors c5 and c6 significantly reduced the via-
bility of all UCCs, with half inhibitory concentrations
between 9 and 20.8 μM. These differences follow the
order of the affinity of the inhibitors for HDAC8 in vitro
[41]. Though in vitro affinity of c5 and c6 is 20 - 50 fold
higher compared to c2, in vivo effects on UCC were not
as strong as expected.
Focusing on morphological features of UCCs, the data
suggested that cells with an epithelial phenotype and low
HDAC8 expression are more sensitive towards pharmaco-
logical inhibition of HDAC8 with c5 and c6 compared to
cells with a mesenchymal phenotype. Specifically, SW-1710
cells (mesenchymal, elevated HDAC8 expression) were
least sensitive to the inhibitors c5 and c6 while RT112
cells (epithelial, lowest HDAC8 expression) responded to
treatment with c5 and c6 already at low concentrations.
As recently shown in endometrial stroma sarcoma cells,
HDAC inhibition may be counteracted by increased activ-
ity of the PI3K pathway in PTEN-deficient cells [45]. In
our cell line panel, UM-UC-3 are PTEN-deficient, result-
ing in increased PI3K activity. However, this cell line was
not exceptionally resistant either in our previous study
using pan-HDAC inhibition [39] or in the present study
with HDAC8-specific inhibitors. Accordingly, at least in
urothelial cancer, PTEN deficiency does not seem to have
a decisive impact on the efficacy of HDAC inhibitors.
Effects of siRNA mediated downregulation and pharma-
cological inhibition on urothelial cancer cell lines were
not thoroughly consistent. Differences might be explained
by several factors. For example, knockdown depletes the
protein thereby not only affecting enzymatic but also
other protein functions for example complex assembly.Inhibitor treatment ideally only suppresses the enzymatic
activity while further protein functions should not be
affected. Accordingly, also compensatory mechanisms
might be different in both conditions. Comparing expres-
sion levels of further class I HDACs after knockdown of
HDAC8 as well as after pharmacological inhibition, only
minor changes were observed. Although upregulation
of HDAC1 or HDAC2 was a little more consistently
observed after HDAC8 knockdown, they can hardly ex-
plain the difference between knockdown and inhibition
by c5 or c6. More likely, the stronger effects of the in-
hibitors may be due to inhibition of other targets in
addition to HDAC8.
Neither HDAC8 knockdown nor pharmacological treat-
ment with any compound (except the SAHA control) led
to a change in histone H3 or H4 acetylation, a widely used
surrogate marker for intracellular HDAC inhibition.
This finding suggests that HDAC8, as expected, does not
substantially affect overall histone acetylation. In addition,
this does also indicate that inhibitor treatment seems to
be iso-enzyme specific as other class I HDACs seemed to
be not affected. This was also observed in neuroblastoma
cell lines after treatment of HDAC8. Global Histone H4
acetylation was not affected by HDAC8 knockdown or by
selective inhibitor treatment [34].
In contrast, HDAC8 knockdown in some cell lines and
treatment with c5 or c6 resulted in a strong increase of
acetylated α-tubulin. The latter finding is in accord with
previous findings in HeLa and HEK293 cells [45]. The
cytoplasmic protein α-tubulin is especially a substrate of
HDAC6 which is predominantly localized in the cyto-
plasm [23]. HDAC6 influences the cytoskeleton and cell
motility via deacetylation of α-tubulin and other cyto-
skeleton proteins [46]. In vitro, c5 and c6 do not inhibit
HDAC6 efficiently. Thus, the best explanation for these
observations is that in vivo HDAC8 directly or indirectly
influences α-tubulin acetylation. Similar discrepancies be-
tween in vitro and in vivo activity of an isoenzyme-selective
HDAC inhibitor on tubulin acetylation have been observed
by others for valproic acid [47]. These effects on α-tubulin
acetylation may relate to the inhibition of cell migration by
c5 and c6 we observed in UC cell lines. However, inhibition
of HDAC6 as such does not inhibit migration of UCC as ef-
ficiently as the HDAC8 inhibitors c5 and c6 [48].
The effects of siRNA mediated knockdown of HDAC8
on cell cycle and apoptosis were limited and few signifi-
cant effects were seen, such as a decreased S-phase
fraction in VM-CUB1 and small changes in thymidy-
late synthase and p21 expression. In the neuroblastoma
cell line BE (2)-C, a G0/G1 arrest has been detected
after siRNA-mediated knockdown of HDAC8. This G0/G1
arrest induced by HDAC8 knockdown was associated with
p21 mRNA upregulation [34]. In contrast, no effect on the
cell cycle was observed in the hepatocellular carcinoma cell
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our own marginal effects after siRNA-mediated HDAC8
knockdown. The level of apoptosis induction in BEL-7402
and Hep-G2 cells after siRNA-mediated targeting of
HDAC8 were comparable to the increase of the subG1-
fraction in individual urothelial carcinoma cell lines after
targeting of HDAC8 [36].
Concerning the use of inhibitors, effects of pharmaco-
logical inhibition on cell cycle distribution by c2 were, as
expected, only minor. In contrast, pharmacological in-
hibition by c5 or c6 resulted in a significant albeit low
increase of the sub-G1 fraction in two out of five cell
lines and in an apparent G2/M-arrest in four out of five
cell lines. Consequently, p21 increased in two cell lines
and thymidylate synthase decreased in all but one.
Conclusions
HDAC8 is deregulated in UCCs resulting in variable
mRNA and protein expression levels. Suppression and
pharmacological inhibition of HDAC8 had significant,
but overall minor impacts on cell proliferation, clonogenic
growth and migration. These effects were comparable
to findings in other cancer entities. Furthermore,
pharmacological inhibition of HDAC8 induced a G2/
M-arrest. However, those effects were observed only at
drug concentrations probably not appropriate for the
use in patients. Neither HDAC8 mRNA nor protein ex-
pression levels were reliable predictive marker for sen-
sitivity to HDAC8 inhibition.
In summary, HDAC8 on its own does not seem to con-
stitute a promising drug target in bladder cancer. Whether
selective HDAC8 inhibition may synergize with either
conventional chemotherapeutics or further targeted anti-
tumoral compounds remains to be further explored. Inter-
estingly, in this respect, the compounds c5 and c6 which
are efficient inhibitors of HDAC8 may have additional
cellular targets which need to be further elucidated.
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